The size of the European PDE Inhibitors market is forecasted to grow at a robust CAGR from 2020 to 2025.
The high sales and market growth of PDE-5 have encouraged pharmaceutical manufacturers to invest more money in further research of PDE Inhibitors market. This is expected to be a key driving factor of the market. Increasing awareness of people towards usage of PDE Inhibitors is propelling the market size.
The PDE Inhibitors market is segmented by Application and by Drug Type. By Application, the market is categorized into Erectile Dysfunction, Cardiovascular Diseases, Benign Prostate Hyperplasia, Respiratory Diseases, Neurological Diseases, Dermatological Disorders, Pulmonary Hypertension, Others. By Drug type, the market is further divided into PDE-1, PDE-2, PDE-3, PDE-4, PDE-5, Viagra, Cialis, Levitra, and others. The increasing demand for PDE-5 from the pediatric patients suffering from Pulmonary Hypertension has helped it to occupy the major market share. Besides, PDE-5 can also be used to treat patients suffering from erectile dysfunction and minor heart attacks, this can further fuel the market size. From the recent studies, we can easily conclude that PDE-5 can be safely suggested to infants and children suffering from Pulmonary Hypertension which can also be attributed to increasing the size of the PDE Inhibitors market. The PDE-4 inhibitor which is used in treating atopic dermatitis and skin disorders is also expected to increase its demand as some of its key manufacturers received FDA approval regarding its production.
By geography, the market is segmented into UK, Germany, Spain, France, and others. Europe PDE Inhibitors Market is showing signs of steady growth owing to the availability of proper healthcare facilities and reimbursement policies.
Some of the major manufacturers playing a leading role in the European PDE Inhibitors Market are Mist Pharmaceuticals, AstraZeneca, Nusirt Biopharma, Takeda Pharmaceuticals, Bayer AG, Pfizer, Otsuka, Eli Lilly, Verona Pharma, Omeros, Hanmi Science Holding, Celgene Corporation.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Application
5.1.1 Introduction
5.1.2 Pulmonary Hypertension
5.1.3 Cardiovascular Diseases
5.1.4 Benign Prostate Hyperplasia
5.1.5 Respiratory Diseases
5.1.6 Neurological Diseases
5.1.7 Dermatological Disorders
5.1.8 Erectile Dysfunction
5.1.9 Other Applications
5.1.10 Y-o-Y Growth Analysis, By Application
5.1.11 Market Attractiveness Analysis, By Application
5.1.12 Market Share Analysis, By Application
5.2 Drug Type
5.2.1 Introduction
5.2.2 Selective PDE inhibitors
5.2.2.1 PDE-1
5.2.2.2 PDE-2
5.2.2.3 PDE-3
5.2.2.4 PDE-4
5.2.2.5 PDE-5
5.2.2.6 Others ( PDE-6 to PDE-11 )
5.2.3 Non-selective PDE inhibitors
5.2.3.1 Viagra
5.2.3.2 Cialis
5.2.3.3 Levitra
5.2.3.4 Other Drugs
5.2.4 Y-o-Y Growth Analysis, By Drug Type
5.2.5 Market Attractiveness Analysis, By Drug Type
5.2.6 Market Share Analysis, By Drug Type
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By Drug Type
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Application
6.1.4.3 By Drug Type
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Application
6.1.5.3 By Drug Type
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Mist Pharmaceuticals
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 AstraZeneca
8.3 Nusirt Biopharma
8.4 Takeda Pharmaceuticals
8.5 Bayer AG
8.6 Pfizer
8.7 Otsuka
8.8 Eli Lilly
8.9 Verona Pharma
8.10 Omeros
8.11 Hanmi Science Holding
8.12 Celgene Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
